Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis

Patrick Mosler, Stuart Sherman, Jeffrey Marks, James L. Watkins, Joseph E. Geenen, Priya Jamidar, Evan Fogel, Laura Lazzell-Pannell, M'Hamed Temkit, Paul Tarnasky, Kevin P. Block, James T. Frakes, Arif A. Aziz, Pramod Malik, Nicholas Nickl, Adam Slivka, John Goff, Glen Lehman

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: Pancreatitis is the most common major complication of ERCP. Efforts have been made to identify pharmacologic agents capable of reducing its incidence and severity. The aim of this trial was to determine whether prophylactic allopurinol, an inhibitor of oxygen-derived free radical production, would reduce the frequency and severity of post-ERCP pancreatitis. Methods: A total of 701 patients were randomized to receive either allopurinol or placebo 4 hours and 1 hour before ERCP. A database was prospectively collected by a defined protocol on patients who underwent ERCP. Standardized criteria were used to diagnose and grade the severity of postprocedure pancreatitis. Results: The groups were similar with regard to patient demographics and to patient and procedure risk factors for pancreatitis. The overall incidence of pancreatitis was 12.55%. It occurred in 46 of 355 patients in the allopurinol group (12.96%) and in 42 of 346 patients in the control group (12.14%; p = 0.52). The pancreatitis was graded mild in 7.89%, moderate in 4.51%, and severe in 0.56% of the allopurinol group, and mild in 6.94%, moderate in 4.62%, and severe in 0.58% of the control group. There was no significant difference between the groups in the frequency or the severity of pancreatitis. Conclusions: Prophylactic oral allopurinol did not reduce the frequency or the severity of post-ERCP pancreatitis.

Original languageEnglish
Pages (from-to)245-250
Number of pages6
JournalGastrointestinal Endoscopy
Volume62
Issue number2
DOIs
StatePublished - Aug 2005

Fingerprint

Allopurinol
Endoscopic Retrograde Cholangiopancreatography
Pancreatitis
Control Groups
Reducing Agents
Incidence
Free Radicals
Placebos
Demography
Databases
Oxygen

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. / Mosler, Patrick; Sherman, Stuart; Marks, Jeffrey; Watkins, James L.; Geenen, Joseph E.; Jamidar, Priya; Fogel, Evan; Lazzell-Pannell, Laura; Temkit, M'Hamed; Tarnasky, Paul; Block, Kevin P.; Frakes, James T.; Aziz, Arif A.; Malik, Pramod; Nickl, Nicholas; Slivka, Adam; Goff, John; Lehman, Glen.

In: Gastrointestinal Endoscopy, Vol. 62, No. 2, 08.2005, p. 245-250.

Research output: Contribution to journalArticle

Mosler, P, Sherman, S, Marks, J, Watkins, JL, Geenen, JE, Jamidar, P, Fogel, E, Lazzell-Pannell, L, Temkit, MH, Tarnasky, P, Block, KP, Frakes, JT, Aziz, AA, Malik, P, Nickl, N, Slivka, A, Goff, J & Lehman, G 2005, 'Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis', Gastrointestinal Endoscopy, vol. 62, no. 2, pp. 245-250. https://doi.org/10.1016/S0016-5107(05)01572-5
Mosler, Patrick ; Sherman, Stuart ; Marks, Jeffrey ; Watkins, James L. ; Geenen, Joseph E. ; Jamidar, Priya ; Fogel, Evan ; Lazzell-Pannell, Laura ; Temkit, M'Hamed ; Tarnasky, Paul ; Block, Kevin P. ; Frakes, James T. ; Aziz, Arif A. ; Malik, Pramod ; Nickl, Nicholas ; Slivka, Adam ; Goff, John ; Lehman, Glen. / Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. In: Gastrointestinal Endoscopy. 2005 ; Vol. 62, No. 2. pp. 245-250.
@article{17b39b5fa34245e89e3fb9b77370ac07,
title = "Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis",
abstract = "Background: Pancreatitis is the most common major complication of ERCP. Efforts have been made to identify pharmacologic agents capable of reducing its incidence and severity. The aim of this trial was to determine whether prophylactic allopurinol, an inhibitor of oxygen-derived free radical production, would reduce the frequency and severity of post-ERCP pancreatitis. Methods: A total of 701 patients were randomized to receive either allopurinol or placebo 4 hours and 1 hour before ERCP. A database was prospectively collected by a defined protocol on patients who underwent ERCP. Standardized criteria were used to diagnose and grade the severity of postprocedure pancreatitis. Results: The groups were similar with regard to patient demographics and to patient and procedure risk factors for pancreatitis. The overall incidence of pancreatitis was 12.55{\%}. It occurred in 46 of 355 patients in the allopurinol group (12.96{\%}) and in 42 of 346 patients in the control group (12.14{\%}; p = 0.52). The pancreatitis was graded mild in 7.89{\%}, moderate in 4.51{\%}, and severe in 0.56{\%} of the allopurinol group, and mild in 6.94{\%}, moderate in 4.62{\%}, and severe in 0.58{\%} of the control group. There was no significant difference between the groups in the frequency or the severity of pancreatitis. Conclusions: Prophylactic oral allopurinol did not reduce the frequency or the severity of post-ERCP pancreatitis.",
author = "Patrick Mosler and Stuart Sherman and Jeffrey Marks and Watkins, {James L.} and Geenen, {Joseph E.} and Priya Jamidar and Evan Fogel and Laura Lazzell-Pannell and M'Hamed Temkit and Paul Tarnasky and Block, {Kevin P.} and Frakes, {James T.} and Aziz, {Arif A.} and Pramod Malik and Nicholas Nickl and Adam Slivka and John Goff and Glen Lehman",
year = "2005",
month = "8",
doi = "10.1016/S0016-5107(05)01572-5",
language = "English",
volume = "62",
pages = "245--250",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis

AU - Mosler, Patrick

AU - Sherman, Stuart

AU - Marks, Jeffrey

AU - Watkins, James L.

AU - Geenen, Joseph E.

AU - Jamidar, Priya

AU - Fogel, Evan

AU - Lazzell-Pannell, Laura

AU - Temkit, M'Hamed

AU - Tarnasky, Paul

AU - Block, Kevin P.

AU - Frakes, James T.

AU - Aziz, Arif A.

AU - Malik, Pramod

AU - Nickl, Nicholas

AU - Slivka, Adam

AU - Goff, John

AU - Lehman, Glen

PY - 2005/8

Y1 - 2005/8

N2 - Background: Pancreatitis is the most common major complication of ERCP. Efforts have been made to identify pharmacologic agents capable of reducing its incidence and severity. The aim of this trial was to determine whether prophylactic allopurinol, an inhibitor of oxygen-derived free radical production, would reduce the frequency and severity of post-ERCP pancreatitis. Methods: A total of 701 patients were randomized to receive either allopurinol or placebo 4 hours and 1 hour before ERCP. A database was prospectively collected by a defined protocol on patients who underwent ERCP. Standardized criteria were used to diagnose and grade the severity of postprocedure pancreatitis. Results: The groups were similar with regard to patient demographics and to patient and procedure risk factors for pancreatitis. The overall incidence of pancreatitis was 12.55%. It occurred in 46 of 355 patients in the allopurinol group (12.96%) and in 42 of 346 patients in the control group (12.14%; p = 0.52). The pancreatitis was graded mild in 7.89%, moderate in 4.51%, and severe in 0.56% of the allopurinol group, and mild in 6.94%, moderate in 4.62%, and severe in 0.58% of the control group. There was no significant difference between the groups in the frequency or the severity of pancreatitis. Conclusions: Prophylactic oral allopurinol did not reduce the frequency or the severity of post-ERCP pancreatitis.

AB - Background: Pancreatitis is the most common major complication of ERCP. Efforts have been made to identify pharmacologic agents capable of reducing its incidence and severity. The aim of this trial was to determine whether prophylactic allopurinol, an inhibitor of oxygen-derived free radical production, would reduce the frequency and severity of post-ERCP pancreatitis. Methods: A total of 701 patients were randomized to receive either allopurinol or placebo 4 hours and 1 hour before ERCP. A database was prospectively collected by a defined protocol on patients who underwent ERCP. Standardized criteria were used to diagnose and grade the severity of postprocedure pancreatitis. Results: The groups were similar with regard to patient demographics and to patient and procedure risk factors for pancreatitis. The overall incidence of pancreatitis was 12.55%. It occurred in 46 of 355 patients in the allopurinol group (12.96%) and in 42 of 346 patients in the control group (12.14%; p = 0.52). The pancreatitis was graded mild in 7.89%, moderate in 4.51%, and severe in 0.56% of the allopurinol group, and mild in 6.94%, moderate in 4.62%, and severe in 0.58% of the control group. There was no significant difference between the groups in the frequency or the severity of pancreatitis. Conclusions: Prophylactic oral allopurinol did not reduce the frequency or the severity of post-ERCP pancreatitis.

UR - http://www.scopus.com/inward/record.url?scp=22544471566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22544471566&partnerID=8YFLogxK

U2 - 10.1016/S0016-5107(05)01572-5

DO - 10.1016/S0016-5107(05)01572-5

M3 - Article

C2 - 16046988

AN - SCOPUS:22544471566

VL - 62

SP - 245

EP - 250

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 2

ER -